Stockscreener 앱 받기
2.05
2.38%
-0.05
시간 외 거래:
2.05
전일 마감가:
$2.10
열려 있는:
$2.13
하루 거래량:
123.39K
Relative Volume:
0.40
시가총액:
$124.18M
수익:
-
순이익/손실:
$-64.86M
주가수익비율:
-1.8304
EPS:
-1.12
순현금흐름:
$-55.66M
1주 성능:
+7.89%
1개월 성능:
+29.75%
6개월 성능:
+68.03%
1년 성능:
+4.59%
1일 변동 폭
$2.02
$2.15
1주일 범위
$1.8662
$2.19
52주 변동 폭
$0.8551
$2.46
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
명칭
Acumen Pharmaceuticals Inc
전화
617-344-4190
주소
1210-1220 WASHINGTON STREET, NEWTON
ABOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.05 | 127.20M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-07-26 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-20 | 재개 | BofA Securities | Buy |
| 2023-05-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 개시 | BTIG Research | Buy |
| 2022-06-30 | 개시 | H.C. Wainwright | Buy |
| 2022-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-07-26 | 개시 | BofA Securities | Neutral |
| 2021-07-26 | 개시 | Credit Suisse | Outperform |
| 2021-07-26 | 개시 | Stifel | Buy |
| 2021-07-26 | 개시 | UBS | Buy |
모두보기
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded to Sell Rating by Wall Street Zen - Defense World
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen presents new research on Alzheimer’s treatment delivery - Investing.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - setenews.com
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - moha.gov.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times
SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug By Investing.com - Investing.com Canada
How to forecast Acumen Pharmaceuticals Inc. trends using time seriesJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Acumen stock maintains Buy rating at Stifel ahead of late-2026 readout - Investing.com UK
Acumen Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease - The Manila Times
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com India
Acumen Pharmaceuticals (NASDAQ: ABOS) doses first patient in Phase 2, 52-week OLE - Stock Titan
Will a bounce in Acumen Pharmaceuticals Inc. offer an exitJobs Report & Expert Curated Trade Setups - newser.com
Acumen Pharmaceuticals Inc (ABOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):